Company: LHI
Filing Date: 2025-02-14
Form Type: DRS/A
Source: 0001213900-25-014190
Chunk: 286

Company: Living Homeopathy International Ltd.
Filing Date: 2025-02-14
Form: DRS/A
Chunk 286
---
 comprehensive income
in accordance with ASC Topic 220, Comprehensive Income, (“ASC 220”). ASC 220 states that all items that are required to be
recognized under accounting standards as components of comprehensive (loss) income be reported in the unaudited interim condensed consolidated
financial statements. Total comprehensive (loss) income consists of two components, net (loss) income and other comprehensive income.
Other comprehensive income refers to revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity
but are excluded from net income. Other comprehensive income consists of a foreign currency translation adjustment resulting from the
Company’s subsidies not using the US$ as the Company’s functional currency.

In the normal course of business, the Company
is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range of matters,
such as government investigations and tax matters. The Company recognizes its liability for such contingency if it determines it is probable
that a loss has occurred, and a reasonable estimate of the loss can be made. The Company may consider many factors in making these assessments
including historical and the specific facts and circumstances of each matter. Based on currently available information, the Company does
not believe that the ultimate outcome of any unresolved matters, individually and in the aggregate, is reasonably possible to have a
material adverse effect on the financial position, results of operations or cash flows.

The Company computes earnings per share in
accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies with complex capital structures to present basic
and diluted EPS. Basic EPS is measured as net income divided by the weighted average number of ordinary shares outstanding for the period.
Diluted presents the dilutive effect on a per share basis of potential ordinary shares (e.g., convertible securities, options and warrants)
as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have
an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of
diluted EPS. For the six months ended September 30, 2024 and 2023, the Company had no potential ordinary shares outstanding that could
potentially dilute EPS in the future.

For the six months ended September 30, 2024
and 2023, no customer accounts for more than 10% of the Company’s revenue.

For the six months ended September 30